It is even possible that the insulin-stimulating, glucagon-suppressing effects of the peptide or a more active synthetic analogue may be useful in the treatment of non-insulin-dependent diabetes, in which both impaired insulin release in response to glucose and persistent hyperglucagonemia are thought to be key pathophysiological abnormalities' (Kreymann, Ghattei, Williams, Bloom)
This initiation precipitates a multitude of alterations in the cellular milieu, notably the augmentation of mitochondrial biogenesis-a mechanism responsible for the genesis of new mitochondria
2024;9:234 Rosenstock J, Sorli CH, Trautmann ME, Morales C, Wendisch U, Dailey G, et al
If side effects persist or worsen, your healthcare provider can help adjust your treatment plan